Skip to Content

Xeomin (incobotulinumtoxinA) Disease Interactions

There are 3 disease interactions with Xeomin (incobotulinumtoxinA):

Major

Botulinum toxin products (Includes Xeomin) ↔ dysphagia/respiratory disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Dysphagia, Pulmonary Impairment, Myasthenia Gravis

Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others can result in swallowing or breathing difficulties. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders as they may be more susceptible to these complications. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders.

Major

Botulinum toxin products (Includes Xeomin) ↔ infection

Severe Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).

Moderate

IncobotulinumtoxinA (Includes Xeomin) ↔ narrow angle glaucoma

Moderate Potential Hazard, Moderate plausibility. Applies to: Glaucoma (Narrow Angle)

Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma. The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders. To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.

Xeomin (incobotulinumtoxinA) drug interactions

There are 379 drug interactions with Xeomin (incobotulinumtoxinA)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide